Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma
RNA-seq (gene expression) · mouse · 16 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 16 samples: 14 distinct titles, 2 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinomaCell reports. Medicine · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE242470_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1013536 and SRA study SRP458850. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 16 sample titles: 14 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7763809 PBS treatment, biological replicate 1
- GSM7763810 PBS treatment, biological replicate 2
- GSM7763811 AKK treatment, biological replicate 1
- GSM7763812 AKK treatment, biological replicate 2
- GSM7763813 mouse 1-2nd week after HFD diet
- GSM7763814 mouse 1-8th week after HFD diet
- GSM7763815 mouse 1-16th week after HFD diet
- GSM7763816 mouse 1-20th week after HFD diet
- GSM7763817 mouse 1-29th week after HFD diet
- GSM7763818 mouse 2-2nd week after HFD diet
- GSM7763819 mouse 2-8th week after HFD diet
- GSM7763820 mouse 2-16th week after HFD diet
- GSM7763821 mouse 2-20th week after HFD diet
- GSM7763822 mouse 2-29th week after HFD diet
- GSM7763823 PBS
- GSM7763824 AKK
- GSE306673 Akkermansia muciniphila contributes to fasting-mediated radioprotection by inducing epigenetic and transcriptional changes in small intestinal epithelial cells 32 samples shares akkermansia, muciniphila, intestinal
- GSE289773 Pyruvate kinase M2 activation reprograms mitochondria in CD8 T cells, enhancing effector functions and efficacy of anti-PD1 therapy 26 samples shares pd1, efficacy
- GSE272309 Investigate the role of B cell in response to anti-PD1 + anti-CTLA in hepatocellular carcinoma 21 samples shares pd1, hepatocellular
- GSE231357 Syndecan-1 inhibition promotes anti-tumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy 14 samples shares pd1, efficacy
- GSE300888 Sequential Platinum and PARP Inhibition Enhances PD1 Immunotherapy Efficacy in Murine Brca2 Mutated Pancreatic Cancer [RNAseq_2] 14 samples shares pd1, efficacy
- GSE300887 Sequential Platinum and PARP Inhibition Enhances PD1 Immunotherapy Efficacy in Murine Brca2 Mutated Pancreatic Cancer [RNAseq_1] 13 samples shares pd1, efficacy
- GSE301139 Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma 12 samples shares pd1, hepatocellular
- GSE231355 Syndecan-1 inhibition promotes anti-tumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy [kdSdc1_RNAseq] 12 samples shares pd1, efficacy
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.